#BEGIN_DRUGCARD DB00914

# AHFS_Codes:
Not Available

# ATC_Codes:
A10BA01

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Azucaps
Cronoformin
D Bretard
DB Comb
DB-Retard
DBI
DBI Monohydrochloride
Debeone
Debinyl
Diabis
Dibein
Dibiraf
Dibotin
Dipar
Feguanide
Fenfoduron
Fenormin
Glukopostin
Glyphen
Insoral
Lentobetic
Meltrol
Meltrol-50
Normoglucina
Phenformix
Retardo

# CAS_Registry_Number:
114-86-3

# ChEBI_ID:
Not Available

# Chemical_Formula:
C10H15N5

# Chemical_IUPAC_Name:
1-carbamimidamido-N-(2-phenylethyl)methanimidamide

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
A biguanide hypoglycemic agent with actions and uses similar to those of metformin. Although it is generally considered to be associated with an unacceptably high incidence of lactic acidosis, often fatal, it is still available in some countries. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290)

# Dosage_Forms:
Not Available

# Drug_Category:
Hypoglycemic Agents

# Drug_Interactions:
Not Available

# Drug_Reference:
9230023	Rosand J, Friedberg JW, Yang JM: Fatal phenformin-associated lactic acidosis. Ann Intern Med. 1997 Jul 15;127(2):170.
9418116	Enia G, Garozzo M, Zoccali C: Lactic acidosis induced by phenformin is still a public health problem in Italy. BMJ. 1997 Nov 29;315(7120):1466-7.

# Drug_Type:
Approved
Small Molecule
Withdrawn

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-0.83

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
210 mg/mL

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Phenformin

# HET_ID:
Not Available

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C10H15N5/c11-9(12)15-10(13)14-7-6-8-4-2-1-3-5-8/h1-5H,6-7H2,(H6,11,12,13,14,15)

# InChI_Key:
InChIKey=ICFJFFQQTFMIBG-UHFFFAOYSA-N

# Indication:
For the reatment of type II diabetes mellitus.

# KEGG_Compound_ID:
C07673

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
914

# Mechanism_Of_Action:
Phenformin binds to the AMP-activated protein kinase (AMPK). AMPK is an ultra-sensitive cellular energy sensor that monitors energy consumption and down-regulates ATP-consuming processes when activated. The biguanide phenformin has been shown to independently decrease ion transport processes, influence cellular metabolism and activate AMPK. Phenformin's hypoglycemic activity is related the effect it has in activating AMPK and fooling insulin sensitive cells into thinking that insulin levels are low and causing the body to use glucose as if in a state of low caloric consumption. This drug also seems to inhibit several varients of ATP-sensitive potassium channels (namely the receptor subtype Kir6.1).

# Melting_Point:
176.5 Â°C

# Molecular_Weight_Avg:
205.2596

# Molecular_Weight_Mono:
205.132745505

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA1000

# Pharmacology:
Used to treat diabetes, phenformin is a biguanide (contains 2 guanidino groups) hypoglycemic agent with actions and uses similar to those of metformin (Glucophage). Both drugs work by (1) decreasing the absorption of glucose by the intestines, (2) decreasing the production of glucose in the liver, and by (3) increasing the body's ability to use insulin more effectively. More specifically, phenformin improves glycemic control by improving insulin sensitivity. Phenformin is generally considered to be associated with an unacceptably high incidence of actic acidosis. In general biguanides should be used only in stable type II diabetics who are free of liver, kidney and cardiovascular problems and who cannot be controlled with diet.

# Predicted_LogP_Hydrophobicity:
-0.72

# Predicted_LogS:
-3

# Predicted_Water_Solubility:
2.32e-01 g/l

# Primary_Accession_No:
DB00914

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
8249

# PubChem_Substance_ID:
46505230

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
APRD00511

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
NC(=N)NC(=N)NCCC1=CC=CC=C1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Beta-Pebg
Beta-Phenethybiguanide
Beta-Phenethylbiguanide
Fenformin
Fenformina [INN-Spanish]
N-Phenethylbiguanide Hydrochloride
PEDG
Phenethylbiguanide Hydrochloride
Phenethyldiguanide
Phenformin HCl
Phenformin Hydrochloride
Phenformine
Phenformine HCl
Phenformine [INN-French]
Phenforminum [INN-Latin]
Phenoformine Hydrochloride
Phenylethylbiguanide

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:19:45 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Phenformin

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP2D6

# Phase_1_Metabolizing_Enzyme_1_ID:
4119

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 2D6

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 2D6
MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVDFQNTPYCFDQ
LRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVF
LARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDK
AVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVLLHIPALAGKV
LRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVA
DLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVI
HEVQRFGDIVPLGVTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEAVWEKPFRFHPEHF
LDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGV
FAFLVSPSPYELCAVPR

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P10635

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17369473	Zhang L, He H, Balschi JA: Metformin and phenformin activate AMP-activated protein kinase in the heart by increasing cytosolic AMP concentration. Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H457-66. Epub 2007 Mar 16.
17603555	Woollhead AM, Sivagnanasundaram J, Kalsi KK, Pucovsky V, Pellatt LJ, Scott JW, Mustard KJ, Hardie DG, Baines DL: Pharmacological activators of AMP-activated protein kinase have different effects on Na+ transport processes across human lung epithelial cells. Br J Pharmacol. 2007 Aug;151(8):1204-15. Epub 2007 Jul 2.
17995453	Chen S, Murphy J, Toth R, Campbell DG, Morrice NA, Mackintosh C: Complementary regulation of TBC1D1 and AS160 by growth factors, insulin and AMPK activators. Biochem J. 2008 Jan 15;409(2):449-59.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
PRKAA1

# Drug_Target_1_GenBank_ID_Gene:
AB022017

# Drug_Target_1_GenBank_ID_Protein:
4115829

# Drug_Target_1_GeneCard_ID:
PRKAA1

# Drug_Target_1_Gene_Name:
PRKAA1

# Drug_Target_1_Gene_Sequence:
>1653 bp
ATGGCGACAGCCGAGAAGCAGAAACACGACGGGCGGGTGAAGATCGGCCACTACATTCTG
GGTGACACGCTGGGGGTCGGCACCTTCGGCAAAGTGAAGGTTGGCAAACATGAATTGACT
GGGCATAAAGTAGCTGTGAAGATACTCAATCGACAGAAGATTCGGAGCCTTGATGTGGTA
GGAAAAATCCGCAGAGAAATTCAGAACCTCAAGCTTTTCAGGCATCCTCATATAATTAAA
CTGTACCAGGTCATCAGTACACCATCTGATATTTTCATGGTGATGGAATATGTCTCAGGA
GGAGAGCTATTTGATTATATCTGTAAGAATGGAAGGCTGGATGAAAAAGAAAGTCGGCGT
CTGTTCCAACAGATCCTTTCTGGTGTGGATTATTGTCACAGGCATATGGTGGTCCATAGA
GATTTGAAACCTGAAAATGTCCTGCTTGATGCACACATGAATGCAAAGATAGCTGATTTT
GGTCTTTCAAACATGATGTCAGATGGTGAATTTTTAAGAACAAGTTGTGGCTCACCCAAC
TATGCTGCACCAGAAGTAATTTCAGGAAGATTGTATGCAGGCCCAGAGGTAGATATATGG
AGCAGTGGGGTTATTCTCTATGCTTTATTATGTGGAACCCTTCCATTTGATGATGACCAT
GTGCCAACTCTTTTTAAGAAGATATGTGATGGGATCTTCTATACCCCTCAATATTTAAAT
CCTTCTGTGATTAGCCTTTTGAAACATATGCTGCAGGTGGATCCCATGAAGAGGGCCTCA
ATCAAAGATATCAGGGAACATGAATGGTTTAAACAGGACCTTCCAAAATATCTCTTTCCT
GAGGATCCATCATATAGTTCAACCATGATTGATGATGAAGCCTTAAAAGAAGTATGTGAA
AAGTTTGAGTGCTCAGAAGAGGAAGTTCTCAGCTGTCTTTACAACAGAAATCACCAGGAT
CCTTTGGCAGTTGCCTACCATCTCATAATAGATAACAGGAGAATAATGAATGAAGCCAAA
GATTTCTATTTGGCGACAAGCCCACCTGATTCTTTTCTTGATGATCATCACCTGACTCGG
CCCCATCCTGAAAGAGTACCATTCTTGGTTGCTGAAACACCAAGGGCACGCCATACCCTT
GATGAATTAAATCCACAGAAATCCAAACACCAAGGTGTAAGGAAAGCAAAATGGCATTTA
GGAATTAGAAGTCAAAGTCGACCAAATGATATTATGGCAGAAGTATGTAGAGCAATCAAA
CAATTGGATTATGAATGGAAGGTTGTAAACCCATATTATTTGCGTGTACGAAGGAAGAAT
CCTGTGACAAGCACTTACTCCAAAATGAGTCTACAGTTATACCAAGTGGATAGTAGAACT
TATCTACTGGATTTCCGTAGTATTGATGATGAAATTACAGAAGCCAAATCAGGGACTGCT
ACTCCACAGAGATCGGGATCAGTTAGCAACTATCGATCTTGCCAAAGGAGTGATTCAGAT
GCTGAGGCTCAAGGAAAATCCTCAGAAGTTTCTCTTACCTCATCTGTGACCTCACTTGAC
TCTTCTCCTGTTGACCTAACTCCAAGACCTGGAAGTCACACAATAGAATTTTTTGAGATG
TGTGCAAATCTAATTAAAATTCTTGCACAATAA

# Drug_Target_1_General_Function:
Involved in protein kinase activity

# Drug_Target_1_General_References:
11042152	Zhang QH, Ye M, Wu XY, Ren SX, Zhao M, Zhao CJ, Fu G, Shen Y, Fan HY, Lu G, Zhong M, Xu XR, Han ZG, Zhang JW, Tao J, Huang QH, Zhou J, Hu GX, Gu J, Chen SJ, Chen Z: Cloning and functional analysis of cDNAs with open reading frames for 300 previously undefined genes expressed in CD34+ hematopoietic stem/progenitor cells. Genome Res. 2000 Oct;10(10):1546-60.
8557660	Stapleton D, Mitchelhill KI, Gao G, Widmer J, Michell BJ, Teh T, House CM, Fernandez CS, Cox T, Witters LA, Kemp BE: Mammalian AMP-activated protein kinase subfamily. J Biol Chem. 1996 Jan 12;271(2):611-4.

# Drug_Target_1_HGNC_ID:
HGNC:9376

# Drug_Target_1_HPRD_ID:
04115

# Drug_Target_1_ID:
748

# Drug_Target_1_Locus:
5p12

# Drug_Target_1_Molecular_Weight:
62808

# Drug_Target_1_Name:
5'-AMP-activated protein kinase catalytic subunit alpha-1

# Drug_Target_1_Number_of_Residues:
550

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00069	Pkinase

# Drug_Target_1_Protein_Sequence:
>5'-AMP-activated protein kinase catalytic subunit alpha-1
MATAEKQKHDGRVKIGHYILGDTLGVGTFGKVKVGKHELTGHKVAVKILNRQKIRSLDVV
GKIRREIQNLKLFRHPHIIKLYQVISTPSDIFMVMEYVSGGELFDYICKNGRLDEKESRR
LFQQILSGVDYCHRHMVVHRDLKPENVLLDAHMNAKIADFGLSNMMSDGEFLRTSCGSPN
YAAPEVISGRLYAGPEVDIWSSGVILYALLCGTLPFDDDHVPTLFKKICDGIFYTPQYLN
PSVISLLKHMLQVDPMKRATIKDIREHEWFKQDLPKYLFPEDPSYSSTMIDDEALKEVCE
KFECSEEEVLSCLYNRNHQDPLAVAYHLIIDNRRIMNEAKDFYLATSPPDSFLDDHHLTR
PHPERVPFLVAETPRARHTLDELNPQKSKHQGVRKAKWHLGIRSQSRPNDIMAEVCRAIK
QLDYEWKVVNPYYLRVRRKNPVTSTYSKMSLQLYQVDSRTYLLDFRSIDDEITEAKSGTA
TPQRSGSVSNYRSCQRSDSDAEAQGKSSEVSLTSSVTSLDSSPVDLTPRPGSHTIEFFEM
CANLIKILAQ

# Drug_Target_1_Reaction:
ATP + a protein = ADP + a phosphoprotein

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Responsible for the regulation of fatty acid synthesis by phosphorylation of acetyl-CoA carboxylase. It also regulates cholesterol synthesis via phosphorylation and inactivation of hormone-sensitive lipase and hydroxymethylglutaryl-CoA reductase. Appears to act as a metabolic stress-sensing protein kinase switching off biosynthetic pathways when cellular ATP levels are depleted and when 5'-AMP rises in response to fuel limitation and/or hypoxia. This is a catalytic subunit

# Drug_Target_1_SwissProt_ID:
Q13131

# Drug_Target_1_SwissProt_Name:
AAPK1_HUMAN

# Drug_Target_1_Synonyms:
AMPK alpha-1 chain
EC 2.7.11.1

# Drug_Target_1_Theoretical_pI:
7.64

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Membrane

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
20188727	Aziz Q, Thomas A, Khambra T, Tinker A: Phenformin has a direct inhibitory effect on the ATP-sensitive potassium channel. Eur J Pharmacol. 2010 May 25;634(1-3):26-32. Epub 2010 Feb 25.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
KCNJ8

# Drug_Target_2_GenBank_ID_Gene:
D50312

# Drug_Target_2_GenBank_ID_Protein:
Not Available

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
KCNJ8

# Drug_Target_2_Gene_Sequence:
>1275 bp
ATGTTGGCCAGAAAGAGTATCATCCCGGAGGAGTATGTGCTGGCGCGCATCGCCGCAGAG
AACCTGCGCAAGCCGCGCATCCGAGACCGCCTCCCCAAAGCCCGCTTCATCGCCAAGAGC
GGGGCCTGCAACCTGGCGCATAAGAACATCCGTGAGCAAGGACGCTTTCTACAGGACATC
TTCACCACCTTGGTGGACCTGAAATGGCGCCACACGCTGGTCATCTTTACCATGTCCTTC
CTCTGCAGCTGGCTGCTCTTCGCTATCATGTGGTGGCTGGTGGCCTTTGCCCATGGGGAC
ATCTATGCTTACATGGAGAAAAGTGGAATGGAGAAAAGTGGTTTGGAGTCCACTGTGTGT
GTGACTAATGTCAGGTCTTTCACTTCTGCTTTTCTCTTCTCCATTGAAGTTCAAGTTACC
ATTGGGTTTGGAGGGAGGATGATGACAGAGGAATGCCCTTTGGCCATCACGGTTTTGATT
CTCCAGAATATTGTGGGTTTGATCATCAATGCAGTCATGTTAGGCTGCATTTTCATGAAA
ACAGCTCAGGCTCACAGAAGGGCAGAAACTTTGATTTTCAGCCGCCATGCTGTGATTGCC
GTCCGAAATGGCAAGCTGTGCTTCATGTTCCGAGTGGGTGACCTGAGGAAAAGCATGATC
ATTAGTGCCTCTGTGCGCATCCAGGTGGTCAAGAAAACAACTACACCTGAAGGGGAGGTG
GTTCCTATTCACCAACTGGACATTCCTGTTGATAACCCAATCGAGAGCAATAACATTTTT
CTGGTGGCCCCTTTGATCATCTGCCACGTGATTGACAAGCGCAGTCCCCTGTATGACATC
TCAGCAACTGACCTGGCCAACCAAGACTTGGAGGTCATAGTTATTCTGGAAGGAGTGGTT
GAAACTACTGGCATCACCACACAAGCACGAACCTCCTACATTGCTGAGGAGATCCAATGG
GGCCACCGCTTTGTGTCCATTGTGACTGAGGAAGAAGGAGTGTATTCTGTGGATTACTCC
AAATTTGGCAACACTGTTAAAGTAGCTGCTCCACGGTGCAGTGCCCGAGAGCTGGATGAG
AAACCTTCCATCCTTATTCAGACCCTCCAAAAGAGTGAACTGTCTCATCAAAATTCTCTG
AGGAAGCGCAACTCCATGAGAAGAAACAATTCCATGAGGAGGAACAATTCTATCCGAAGG
AACAATTCTTCCCTCATGGTACCAAAGGTGCAATTTATGACTCCAGAAGGAAATCAAAAC
ACATCGGAATCATGA

# Drug_Target_2_General_Function:
Involved in inward rectifier potassium channel activity

# Drug_Target_2_General_References:
8595887	Inagaki N, Inazawa J, Seino S: cDNA sequence, gene structure, and chromosomal localization of the human ATP-sensitive potassium channel, uKATP-1, gene (KCNJ8). Genomics. 1995 Nov 1;30(1):102-4.

# Drug_Target_2_HGNC_ID:
HGNC:6269

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
4209

# Drug_Target_2_Locus:
12p11.23

# Drug_Target_2_Molecular_Weight:
47969

# Drug_Target_2_Name:
ATP-sensitive inward rectifier potassium channel 8

# Drug_Target_2_Number_of_Residues:
424

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Amlodipine Pathway	SMP00376
Benazepril Pathway	SMP00145
Captopril Pathway	SMP00146
Cilazapril Pathway	SMP00147
Diltiazem Pathway	SMP00359
Disopyramide Pathway	SMP00325
Enalapril Pathway	SMP00148
Felodipine Pathway	SMP00377
Flecainide Pathway	SMP00331
Fosinopril Pathway	SMP00149
Fosphenytoin (Antiarrhythmic) Pathway	SMP00326
Ibutilide Pathway	SMP00332
Isradipine Pathway	SMP00378
Lidocaine (Antiarrhythmic) Pathway	SMP00328
Lisinopril Pathway	SMP00150
Mexiletine Pathway	SMP00329
Moexipril Pathway	SMP00151
Nifedipine Pathway	SMP00379
Nimodipine Pathway	SMP00380
Nisoldipine Pathway	SMP00381
Nitrendipine Pathway	SMP00382
Perindopril Pathway	SMP00152
Phenytoin (Antiarrhythmic) Pathway	SMP00327
Procainamide (Antiarrhythmic) Pathway	SMP00324
Quinapril Pathway	SMP00153
Quinidine Pathway	SMP00323
Ramipril Pathway	SMP00154
Rescinnamine Pathway	SMP00155
Spirapril Pathway	SMP00156
Tocainide Pathway	SMP00330
Trandolapril Pathway	SMP00157
Verapamil Pathway	SMP00375

# Drug_Target_2_Pfam_Domain_Function:
PF01007	IRK

# Drug_Target_2_Protein_Sequence:
>ATP-sensitive inward rectifier potassium channel 8
MLARKSIIPEEYVLARIAAENLRKPRIRDRLPKARFIAKSGACNLAHKNIREQGRFLQDI
FTTLVDLKWRHTLVIFTMSFLCSWLLFAIMWWLVAFAHGDIYAYMEKSGMEKSGLESTVC
VTNVRSFTSAFLFSIEVQVTIGFGGRMMTEECPLAITVLILQNIVGLIINAVMLGCIFMK
TAQAHRRAETLIFSRHAVIAVRNGKLCFMFRVGDLRKSMIISASVRIQVVKKTTTPEGEV
VPIHQLDIPVDNPIESNNIFLVAPLIICHVIDKRSPLYDISATDLANQDLEVIVILEGVV
ETTGITTQARTSYIAEEIQWGHRFVSIVTEEEGVYSVDYSKFGNTVKVAAPRCSARELDE
KPSILIQTLQKSELSHQNSLRKRNSMRRNNSMRRNNSIRRNNSSLMVPKVQFMTPEGNQN
TSES

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
This potassium channel is controlled by G proteins. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium. Can be blocked by external barium (By similarity)

# Drug_Target_2_SwissProt_ID:
Q15842

# Drug_Target_2_SwissProt_Name:
IRK8_HUMAN

# Drug_Target_2_Synonyms:
Inwardly rectifier K(+) channel Kir6.1
Potassium channel, inwardly rectifying subfamily J member 8
uKATP-1

# Drug_Target_2_Theoretical_pI:
9.70

# Drug_Target_2_Transmembrane_Regions:
70-94
155-176

#END_DRUGCARD DB00914
